New antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries at reduced price
NW YORK, N.Y. – A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year. The agreement is expected to accelerate treatment rollout as part…